About Blue Water Acquisition Corp
Blue Water Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded in 2020 and is based in Greenwich, Connecticut. Address: 15 East Putnam Avenue, Greenwich, CT, United States, 06830
Blue Water Acquisition Corp News and around…
Latest news about Blue Water Acquisition Corp (BLUWU) common stock and company :
Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc.’s common stock and warrants will commence trading on the Nasdaq Global Market on September 10, 2021, under the ticker symbols “CRXT” and “CRXTW,” respectively Gross proceeds totaled approximately $25.3 million NORTHBROOK, Ill. and GREENWICH, Conn., Sept. 09, 2021 (GLOBE NE
Gainers Blue Water Acquisition Corp. (NASDAQ: BLUW) shares climbed 57% to $16.41. Blue Water Acquisition is expected to hold a special meeting of its stockholders on Friday, August 27, 2021. Ascendis Pharma A/S (NASDAQ: ASND) shares climbed 28.7% to $158.68 after the company reported Q2 earnings results. Several analysts raised their price targets on the stock. Lordstown Motors Corp. (NASDAQ: RIDE) gained 23.3% to $6.80 after the company announced its board of directors has appointed Daniel A. N
Blue Water Acquisition Corp. (Nasdaq: BLUW) ("Blue Water"), a special purpose acquisition company ("SPAC") led by Joseph Hernandez, today announced that it has scheduled a special meeting of its stockholders (the "Special Meeting") to, among other things, consider and vote on a proposal to approve the transactions contemplated by the previously announced merger agreement pursuant to which Clarus Therapeutics, Inc. ("Clarus") will merge with a wholly-owned subsidiary of Blue Water (the "Business
Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and HavaH Therapeutics ("HavaH"), an Australia-based biopharmaceutical company developing androgen therapies for inflammatory breast disease and certain forms of breast cancer by using the innate breast-tissue-specific hormone/immune interface, today announced a licensing agreement whereby Clarus will acquire the exclusive worldwide (excluding Australia) development and commercialization rights for HAVAH T+Ai™ (CLAR-121).
Blue Water Acquisition Corp. (NASDAQGS: BLUW)
WILMINGTON, Del., May 05, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Blue Water Acquisition Corp. (“Blue Water”) (NASDAQ GS: BLUW) regarding possible breaches of fiduciary duties and other violations of law related to Blue Water’s agreement to merge with Clarus Therapeutics, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-blue-water-acquisition-corp. You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or firstname.lastname@example.org. Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide. Attorney advertising. Prior results do not guarantee a similar outcome. CONTACT: Rigrodsky Law, P.A.Seth D. RigrodskyGina M. Serra(888) 969-4242 (Toll Free)(302) 295-5310Fax: (302) email@example.com https://rl-legal.com
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Blue Water Acquisition Corp. ("BLUW" or the "Company") (BLUW) relating to its proposed merger with Clarus Therapeutics, Inc. Under the terms of the agreement, BLUW will acquire Clarus through a reverse merger, with Clarus emerging as a publicly traded company.
BALA CYNWYD, PA / ACCESSWIRE / May 3, 2021 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions.
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
BALA CYNWYD, PA / ACCESSWIRE / April 27, 2021 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Blue Water Acquisition Corp. ("Blue Water" or the "Company") (Nasdaq:BLUW) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which Blue Water, a special purpose acquisition company, will combine with Clarus Therapeutics Inc.
Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and Blue Water Acquisition Corp. (NASDAQ: BLUW) ("Blue Water"), a special purpose acquisition company (SPAC), today announced a definitive business combination agreement that will result in Clarus becoming a publicly traded company. This transaction values Clarus at $379 million on a fully diluted basis, assuming no redemptions by Blue Water stockholders. In addition, current Clarus stakeholders will invest an additional $25 million in Clarus following the announcement of this transaction. Subject to stockholder approval and the satisfaction of customary closing conditions, the business combination transaction is expected to close in the third quarter of 2021.
New York, NY, April 22, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ: BLUWU) (the “Company”) announced today that it received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2020 (the “Form 10-K”) with the Securities and Exchange Commission (“SEC”). The Notice has no immediate effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. As previously disclosed in the Current Report on Form 8-K filed on April 15, 2021 by the Company, on April 12, 2021, the staff (the “Staff”) of the Division of Corporation Finance of the SEC issued a statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies” (the “Staff Statement”). The Staff Statement, among other things, highlighted the potential accounting implications of certain terms that are common in warrants issued in connection with the initial public offerings of special purpose acquisition companies (“SPAC”) such as the Company. The Company is continuing to evaluate its financial statements for the year ended December 31, 2020 to be included in the Form 10-K to determine whether its public and private warrants may be required to be accounted for as liabilities, rather than equity, in the Form 10-K. The Company is working diligently to finalize the financial statements and to file the Form 10-K as soon as practicable. Under Nasdaq rules, the Company has 60 calendar days from the date of the Notice, or until June 15, 2021, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company's plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-K, or until October 12, 2021, to regain compliance. About Blue Water Acquisition Corp. Blue Water Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue targets in any industry, it intends to focus its search in the healthcare industry. Forward-Looking Statements This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact: Russo Partners David Schull (858) 717-2310 firstname.lastname@example.org Ignacio Guerrero-Ros, Ph.D. (646) 942-5604 Ignacio.Guerrero-Ros@russopartnersllc.com
Blue Water Acquisition Corporation (NASDAQ: BLUWU) (the "Company"), a special purpose acquisition company, announced today that it closed its initial public offering of 5,750,000 units, which includes 750,000 units issued pursuant to the full exercise by the underwriter of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $57,500,000. Each unit consisted of one share of the Company's Class A common stock and one redeemable warrant to purchase one share of Class A common stock at an initial exercise price of $11.50 per share.